Peptide YY vs Pramlintide
Research Verdict
Pramlintide is the stronger research reference for the stated comparison criteria. Pramlintide: FDA approved for T1DM and T2DM as adjunct to insulin, published Phase 3 data showing HbA1c reduction and modest weight loss.
Quick Answers
Which is better, Peptide YY or Pramlintide?
Pramlintide is the stronger research reference for the stated comparison criteria. Pramlintide: FDA approved for T1DM and T2DM as adjunct to insulin, published Phase 3 data showing HbA1c reduction and modest weight loss.
What is the key difference between Peptide YY and Pramlintide?
Pramlintide is a synthetic amylin analog that slows gastric emptying and suppresses glucagon; PYY is an endogenous gut satiety hormone - overlapping appetite effects but different primary mechanisms and regulatory maturity.
Evidence Comparison
Pramlintide: FDA approved for T1DM and T2DM as adjunct to insulin, published Phase 3 data showing HbA1c reduction and modest weight loss. PYY(3-36): Phase 2 human data confirming appetite suppression (Batterham et al. 2003, NEJM) but development stalled due to nausea at effective doses. Pramlintide has the regulatory approval.
Evidence Context Favoring Peptide YY
Research into endogenous satiety signaling or PYY-specific gut-brain axis mechanisms, accepting that clinical development is stalled.
Evidence Context Favoring Pramlintide
Diabetes management or appetite suppression research requiring an approved agent with established dosing and safety data.
Side-by-Side Snapshot
| Evidence grade | Peptide YY: Level C Pramlintide: Level A |
|---|---|
| Research status | Peptide YY: Phase 1 Pramlintide: FDA Approved |
| Primary category | Peptide YY: Weight Loss & Metabolic Pramlintide: Weight Loss & Metabolic |
| Cited studies | Peptide YY: 2 Pramlintide: 3 |